Background-Previous studies implicated Toll-like receptor signaling as a critical pathogenic pathway in atherosclerosis, but the cell-specific mechanisms by which Toll-like receptors act to control atherosclerotic plaque development remain poorly understood. Methods and Results-To study the cell-specific role of tumor necrosis factor receptor-associated factor 6 (TRAF6) in atherosclerosis, we generated ApoE Ϫ/Ϫ mice with endothelial cell-or myeloid cell-specific TRAF6 deficiency using Cre/LoxP-mediated gene targeting. Endothelial TRAF6 deficiency reduced atherosclerosis in female ApoE Ϫ/Ϫ mice by inhibiting nuclear factor-B-dependent proinflammatory gene expression and monocyte adhesion to endothelial cells.
regulating innate immune responses essential for host defense. 7 In addition to pathogen-associated molecular patterns, TLRs recognize endogenous ligands that are related to atherosclerosis such as modified low-density lipoprotein (LDL) and heat shock protein-60, suggesting that TLRmediated responses may contribute to the pathogenesis of atherosclerosis. 8 Indeed, both resident cells and recruited leukocytes within atherosclerotic plaques were shown to express TLR1, TLR2, TLR4, and TLR5. 4, 8, 9 Functional analysis of the role of TLRs in an in vitro model of human atherosclerosis suggested that TLR2 is the main receptor mediating inflammation and matrix degradation. 10 Moreover, increased expression of TLR2 in monocytes was recently identified as an important risk factor for atherosclerosis. 11 The first direct in vivo evidence that TLR signaling is important for the pathogenesis of atherosclerosis came from the observation that ApoE Ϫ/Ϫ mice lacking MyD88, an adapter protein required for signaling downstream of all TLRs except TLR3, are protected from diet-induced atherosclerosis. 12 Furthermore, TLR4 deficiency was associated with a significant reduction of aortic plaque size, lipid content, and macrophage infiltration in ApoE Ϫ/Ϫ mice. 13 However, MyD88 deficiency had a stronger impact on inhibiting atherosclerosis compared with the TLR4 knockout effect, suggesting that other TLR signaling via MyD88 might also contribute to the development of atherosclerosis. Indeed, TLR2 gene ablation modestly reduced atherosclerosis severity in LDLR Ϫ/Ϫ mice, an effect proposed to be mediated by nonhematopoietic cells of the vascular wall. 14 However, more recent experiments also provided evidence for a proatherogenic role of TLR2 in hematopoietic cells. 15 Furthermore, administration of a TLR2 agonist increased the severity of atherosclerosis in the ApoE Ϫ/Ϫ mouse model, an effect dependent on TLR2 expression in bone marrow-derived cells. 16 In contrast to the proatherogenic roles attributed to TLR2 and TLR4, a recent study showed that TLR3 deficiency accelerated the onset of atherosclerosis in ApoE Ϫ/Ϫ mice, 17 suggesting that TLR3 exerts antiatherogenic functions. Although these studies established TLR signaling as a crucial regulator of atherosclerosis, the mechanisms by which TLRs contribute to the initiation and progression of atherosclerotic plaque development remain poorly understood. Elucidating the cell-specific function of TLR signaling in atherosclerotic plaque development is essential for understanding the mechanisms by which these receptors contribute to the pathogenesis of atherosclerosis.
Tumor necrosis factor receptor-associated factor 6 (TRAF6) is an E3 ubiquitin ligase that is essential for signaling downstream of the interleukin (IL)-1 receptor/TLR superfamily and of specific members of the tumor necrosis factor receptor superfamily (CD40 and receptor activator of nuclear factor-B [NF-B]). 18, 19 Specifically for TLR signaling, TRAF6 participates in both the MyD88-and TRIF-dependent pathways and therefore plays a crucial role in signaling by all TLRs. 20 In the present study, we addressed the cell-specific function of TRAF6 in atherosclerosis using genetic mouse models. Our results revealed opposing functions of TRAF6mediated TLR signaling in endothelial cells and macrophages. Endothelial cell-specific TRAF6 deficiency reduced the severity of atherosclerosis in female ApoE Ϫ/Ϫ mice by inhibiting TLR-induced NF-B-mediated expression of proinflammatory mediators in the vascular endothelium. In contrast, both male and female ApoE Ϫ/Ϫ mice lacking TRAF6 specifically in myeloid cells surprisingly showed more severe atherosclerosis. We found that TRAF6-deficient macrophages showed reduced IL-10 expression, increased endoplasmic reticulum (ER) stress, and increased apoptosis when stimulated with oxidized LDL (oxLDL) and displayed a reduced capacity to scavenge apoptotic bodies in vitro. These results suggest that TLR-mediated TRAF6 signaling in macrophages is atheroprotective by regulating both the antiinflammatory response and the survival and efferocytosis capacity of macrophages in vivo.
Methods
A detailed Methods section can be found in the online-only Data Supplement.
Mice and Diet
Mice with conditional loxP-flanked Traf6 (Traf6 FL ) alleles were generated by gene targeting in C57Bl/6 (Bruce4) ES cells and were crossed with Tie2CreER T2 21 or LysMCre 22 to generate endotheliumand myeloid-specific TRAF6 knockouts, respectively. To study the role of TRAF6 in atherosclerosis, these mice were then crossed with ApoE Ϫ/Ϫ mice. For induction of Cre-mediated DNA recombination, mice carrying the Tie2CreER T2 transgene and their Cre-negative littermates were fed a tamoxifen-containing diet for 6 weeks starting at the age of 6 to 7 weeks. For atherosclerosis development, all mice were placed on a high-fat diet for 10 weeks before death. All animal procedures were conducted in accordance with European, national, and institutional guidelines and protocols and were approved by local governmental authorities.
Additional Methods
The expanded Methods section in the online-only Data Supplement contains information on the mice and the diet used; lipid analysis; immunostainings; histology; assessments of lesion size; oxidation and labeling of LDL; isolation and culture of cells; adhesion assay; apoptosis assay; efferocytosis assay; foam cell formation assay; immunoblot analysis; Southern blotting; and quantitative reverse transcription-polymerase chain reaction analysis.
Statistical Analysis
Continuous variables were summarized by meanϮSEM. Regarding mean values, pairwise comparisons of groups were evaluated by either the unpaired t test or the nonparametric Mann-Whitney test contingent on the presence of heavy tails or outliers/skewness. Moreover, multiple pairwise comparisons of groups over time were evaluated by repeated measures 2-way ANOVA with Bonferroni post hoc tests (Corrected P values are given for comparison between genotypes at each time point). The usual family-wise type I error of 5% was adopted to assess statistical significance. All analyses were done with Prism (GraphPad Software Inc, San Diego, CA).
Results

TRAF6 Ablation in Endothelial Cells Reduced Atherosclerotic Plaque Development in Female ApoE Ϫ/Ϫ Mice
To study in vivo the role of TRAF6 in the vascular endothelium, we used mice with inducible endothelial cell-restricted TRAF6 deficiency (TRAF6 ECiKO ), generated by crossing mice with loxP-flanked TRAF6 alleles ( Figure IA in the online-only Data Supplement) to Tie2-CreER T2 mice. 21 TRAF6 ECiKO mice were further crossed to ApoE Ϫ/Ϫ mice, a widely used mouse model of atherosclerosis. Cre-mediated excision of the floxed TRAF6 alleles in endothelial cells ( Figure IB and IC in the online-only Data Supplement) was achieved by feeding groups of TRAF6 ECiKO /ApoE Ϫ/Ϫ mice and their TRAF6 FL/FL /ApoE Ϫ/Ϫ littermates (hereafter referred to as ApoE Ϫ/Ϫ for simplicity) tamoxifen-containing chow diet for 6 weeks as previously described. 23 The mice were subsequently placed on a high-fat diet (HFD) for 10 weeks. TRAF6 ECiKO /ApoE Ϫ/Ϫ and ApoE Ϫ/Ϫ mice showed similar body weights and serum levels of triglycerides and cholesterol after HFD treatment ( Figure 1A-1C ), indicating that endothelium-specific deletion of TRAF6 did not affect basic metabolic features.
Histological analysis of heart sections at the level of the aortic sinus showed significantly decreased atherosclerotic lesion development in female TRAF6 ECiKO Figure IIA and IIB in the online-only Data Supplement). Importantly, control experiments in ApoE Ϫ/Ϫ /Tie2CreER T2 mice that did not contain TRAF6 FL alleles showed that neither tamoxifen treatment nor Tie2-CreER T2 expression had a measurable effect on the development of atherosclerosis in this model ( Figure IIIA and IIIB in the online-only Data Supplement). Thus, endothelium-specific TRAF6 deficiency could reduce the severity of atherosclerosis in female but not in male mice.
Reduced Chemokine and Adhesion Molecule Expression and Macrophage Recruitment in Plaques From Female TRAF6 ECiKO /ApoE Ϫ/Ϫ Mice
To dissect the mechanisms by which endothelial TRAF6 deficiency reduced atherosclerosis severity, we focused on the analysis of female TRAF6 ECiKO /ApoE Ϫ/Ϫ mice. We hypothesized that endothelial TRAF6 deficiency reduced atherosclerosis severity by inhibiting the expression of chemokines and adhesion molecules in the endothelium, resulting in impaired recruitment of macrophages to the developing plaques. Indeed, immunostaining with MOMA-2 antibodies revealed considerably decreased macrophage content in plaques from female TRAF6 ECiKO /ApoE Ϫ/Ϫ mice compared with their female ApoE Ϫ/Ϫ littermates (Figure 2A and 2B). Gene expression analysis revealed reduced expression of a number of chemokines, including interferon-inducible protein-10, macrophage inflammatory protein-1a/1b/2a, Fraktalkine, and Gro-KC in aortas from female TRAF6 ECiKO /ApoE Ϫ/Ϫ mice compared with their ApoE Ϫ/Ϫ littermates. Moreover, IL-6 and vascular cell adhesion molecule-1 were also expressed at considerably lower levels in aortas from TRAF6 ECiKO /ApoE Ϫ/Ϫ mice ( Figure 2C -2E). Interestingly, increased expression of transforming growth factor-␤ was observed in the aortas of TRAF6 ECiKO /ApoE Ϫ/Ϫ mice, arguing for enhanced antiinflammatory responses in these mice. These results suggest that ablation of TRAF6 in endothelial cells ameliorated atherosclerotic plaque development by inhibiting the expression of vascular cell adhesion molecule-1 and of several chemokines in the vascular endothelium, resulting in impaired macrophage recruitment into the developing plaques.
TRAF6 Deficiency in Endothelial Cells Inhibited OxLDL-Induced NF-B Activation, Inflammatory Gene Expression, and Monocyte/Macrophage Adhesion
We previously demonstrated that NF-B inhibition in endothelial cells protects ApoE Ϫ/Ϫ mice from atherosclerosis by inhibiting the expression of adhesion molecules and chemokines in the vascular wall, resulting in impaired macrophage recruitment into the plaques. 23 Modified lipids were shown to bind TLRs 24 and to activate NF-B signaling in endothelial cells. 25 We therefore reasoned that TRAF6 deficiency reduced atherosclerosis by inhibiting modified lipid-induced NF-B activation and the expression of proinflammatory mediators in endothelial cells. To address whether TRAF6 deficiency inhibits oxLDL-induced inflammatory responses, we analyzed wild-type and TRAF6-deficient primary mouse lung endothelial cells (MLECs). Immunoblotting of protein extracts with antibodies recognizing the phosphorylated forms of IB␣ and Jun N-terminal kinase (JNK) showed that TRAF6-deficient MLECs showed strongly reduced NF-B and JNK activation in response to oxLDL stimulation compared with MLECs expressing TRAF6 ( Figure 3A ). Moreover, TRAF6 deficiency strongly inhibited oxLDL-induced expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, E-selectin, monocyte chemoattractant protein-1, and monocyte chemoattractant protein-3 in MLECs ( Figure 3B -3F). To directly address the capacity of oxLDLstimulated TRAF6-deficient endothelial cells to attract monocytes, we used a static-adhesion assay measuring the ability of wild-type monocytes to adhere to wild-type or TRAF6deficient endothelial cells. This experiment revealed that monocyte adhesion on oxLDL-stimulated Traf6 Ϫ/Ϫ /ApoE Ϫ/Ϫ MLECs was considerably reduced compared with ApoE Ϫ/Ϫ MLEC ( Figure 3G ). Therefore, TRAF6 is essential for NF-B activation and the expression of chemoattractant chemokines and adhesion molecules in endothelial cells in response to oxLDL-induced TLR stimulation.
Macrophage TRAF6 Deficiency Exacerbates Atherosclerosis Development
Our results described above revealed a proatherogenic role of TRAF6-dependent signaling in endothelial cells, acting downstream of TLRs to induce an NF-B-dependent proinflammatory gene expression program that facilitates the recruitment of monocytes into the developing plaques. We then asked whether TRAF6 also acts in myeloid cells to promote atherosclerosis. To address the role of TRAF6 in myeloid cells in the pathogenesis of atherosclerosis, we crossed Traf6 FL/FL /ApoE Ϫ/Ϫ mice with LysM-Cre mice. 22 These TRAF6 MYKO /ApoE Ϫ/Ϫ mice showed efficient deletion of TRAF6 in peritoneal macrophages, as revealed by Southern blot and immunoblot analysis ( Figure ID and IE in the online-only Data Supplement). To study the development of atherosclerosis, groups of TRAF6 MYKO /ApoE Ϫ/Ϫ mice and ApoE Ϫ/Ϫ littermates were fed an HFD for 10 weeks starting at 6 weeks of age. Both groups of mice showed similar body weights and serum levels of triglycerides and total cholesterol on being fed an HFD ( Figure 4A -4C), demonstrating that myeloid TRAF6 deficiency did not affect basic metabolic features. After 10 weeks of HFD feeding, we assessed atherosclerosis development by histological analysis of heart sections at the level of the aortic sinus. Quantification of . This result was surprising and contrary to our expectation that myeloid TRAF6 deficiency would have an atheroprotective effect. To address whether TRAF6 deficiency increased macrophage homing into the plaques, we stained aortic sinus sections from TRAF6 MYKO /ApoE Ϫ/Ϫ mice and ApoE Ϫ/Ϫ littermate controls with anti-MOMA-2 antibodies. Plaques in both groups of mice showed similar macrophage content, suggesting that TRAF6 deficiency did not alter the capacity of macrophages to home into the developing lesions ( Figure 4F and 4G).
Reduced Expression of IL-10 in Aortas From TRAF6 MYKO /ApoE Ϫ/Ϫ Mice
To obtain clues about the potential mechanisms by which TRAF6 knockout in myeloid cells exacerbates atherosclerosis, we measured the expression of chemokines, cytokines, and adhesion molecules in RNA isolated from aortic branches of ApoE Ϫ/Ϫ or TRAF6 MYKO /ApoE Ϫ/Ϫ littermates fed an HFD Figure VA) mice. To assess whether the observed decrease in IL-10 production in the aortas was caused by an impair-ment of IL-10 expression in TRAF6-deficient macrophages, we stimulated TRAF6-deficient or wild-type bone marrowderived macrophages with oxLDL and measured activation of NF-B and JNK and the expression of IL-10, tumor necrosis factor, and IL-6. As shown in Figure 5D , IB␣ phosphorylation and degradation were delayed and reduced and JNK phosphorylation was strongly inhibited in TRAF6-deficient macrophages. In addition, RNA expression analysis revealed that Traf6 Ϫ/Ϫ macrophages expressed considerably reduced levels of IL-10 compared with control cells after stimulation with oxLDL ( Figure 5E ). TRAF6-deficient macrophages also Figure VIB in the onlineonly Data Supplement) compared with wild-type cells. Thus, TRAF6 deficiency in macrophages resulted in decreased IL-10 expression in atherosclerotic plaques in vivo and in cultured macrophages. Because IL-10 has been shown to negatively regulate atherosclerotic plaque development, 26 reduced IL-10 expression is likely to contribute to the development of more severe atherosclerosis in TRAF6 MYKO / ApoE Ϫ/Ϫ mice.
TRAF6-Deficient Macrophages Show Increased Sensitivity to ER Stress and Impaired Efferocytosis
IB kinase-2 deficiency in macrophages resulted in exacerbated atherosclerotic plaque development associated with reduced expression of IL-10, 27 similar to our findings with TRAF6 MYKO / ApoE Ϫ/Ϫ presented here. In addition, mice with myeloid IB kinase-2 deficiency showed increased apoptosis in atherosclerotic plaques. 27 We therefore assessed whether TRAF6 deficiency in macrophages also resulted in increased cell death in atherosclerotic plaques by measuring the necrotic core area in lesions from TRAF6 MYKO A recent study showing that TLR signaling suppresses ER stress-induced C/Ebp-homologous protein (CHOP) expression and death in macrophages 28 prompted us to test whether TRAF6 deficiency affects the expression of CHOP in atherosclerotic plaques. Indeed, we found increased CHOP expression in lesion areas from both male ( Figure 6E ) and female ( Figure VD in the online-only Data Supplement) TRAF6 MYKO /ApoE Ϫ/Ϫ mice, suggesting that TRAF6 deficiency results in elevated CHOP levels in macrophages. Because an analysis of total aorta tissue cannot specifically address the role of TRAF6 in controlling CHOP expression in macrophages, we used bone marrow-derived macrophage cultures to directly address whether loss of TRAF6 results in increased CHOP levels. Traf6 FL/FL or Traf6 Ϫ/Ϫ bone marrow macrophages were prestimulated with 2 ng/mL LPS for 20 hours, followed by stimulation with 3 g/mL tunicamycin, to induce ER stress. Immunoblot analysis of protein extracts prepared 3, 6, or 9 hours after tunicamycin stimulation showed that LPS pretreatment indeed prevented CHOP expression in wild-type macrophages ( Figure 6F ), as previously reported. 28 In contrast, LPS pretreatment failed to suppress CHOP expression in macrophages lacking TRAF6, demonstrating that TRAF6 is an essential mediator of TLR4induced suppression of CHOP expression. Furthermore, TRAF6-deficient bone marrow-derived macrophages expressed increased amounts of CHOP mRNA compared with wild-type cells in response to oxLDL stimulation ( Figure  6G ). Increased ER stress and defective IL-10 signaling may lead to increased apoptosis of macrophages both in vitro and in vivo. Indeed, oxLDL stimulation induced more apoptosis in peritoneal macrophages from TRAF6 MYKO /ApoE Ϫ/Ϫ mice compared with ApoE Ϫ/Ϫ cells ( Figure 6H ). The differential responses of TRAF6-deficient macrophages to oxLDL stimulation were not caused by an impairment of oxLDL uptake because these cells retained a normal capacity to take up oxLDL compared with wild-type macrophages ( Figure 7A ).
Clearance of apoptotic macrophages is an important mechanism limiting plaque growth and atherosclerosis progression. 29 To assess whether TRAF6 deficiency compromised macrophage efferocytosis, we measured the capacity of TRAF6-deficient macrophages to clear apoptotic cells. Indeed, peritoneal macrophages from TRAF6 MYKO /ApoE Ϫ/Ϫ mice exhibited reduced efficiency to clear apoptotic Jurkat T cells compared with peritoneal macrophages from ApoE Ϫ/Ϫ mice ( Figure 7B ). Scavenger receptors have previously been implicated in the recognition and clearance of apoptotic cells. 30, 31 Consistent with their impaired efferocytosis capacity, TRAF6-deficient naïve peritoneal macrophages expressed reduced amounts of SR-AI/II (Figure 7D and 7E) and CD36 ( Figure 7F and 7G ). This reduced cell surface expression of scavenger receptors did not affect the formation of foam cells by Traf6 Ϫ/Ϫ /ApoE Ϫ/Ϫ macrophages in vitro (Figure 7H and 7I ). IL-10 within the atherosclerotic lesions is also produced from macrophages during efferocytosis. 32 Considering that we found reduced IL-10 expression in aortic lesions from TRAF6 MYKO /ApoE Ϫ/Ϫ mice, we tested whether TRAF6-deficient macrophages exhibit reduced IL-10 expression on exposure to apoptotic cells. Indeed, we found that TRAF6-deficient macrophages failed to upregulate IL-10 expression when stimulated by apoptotic Jurkat T cells ( Figure 7C ). Taken together, these results show that TRAF6 deficiency sensitized macrophages to oxLDL-induced apoptosis and reduced their efferocytosis and antiinflammatory properties, resulting in exacerbated atherosclerosis.
Discussion
Atherosclerotic plaque develops and grows as a result of a chronic nonresolving inflammatory response involving the activation of the vascular endothelium at the early stages, a constant influx and entrapment of monocytes, and impaired clearance of dying macrophages within the plaque. Therefore, the mechanisms regulating the recruitment of monocytes and the death and clearance of lipid-laden macrophages in atheromatous plaques are critical for the pathogenesis of athero- sclerosis. Our results presented here show that TRAF6dependent TLR signaling exerts opposing functions in endothelial cells and macrophages in atherosclerosis. TRAF6 deficiency in endothelial cells inhibited the expression of proinflammatory mediators and of the adhesion molecule vascular cell adhesion molecule-1, resulting in reduced macrophage influx and smaller atherosclerotic plaques in female mice. Moreover, TRAF6-deficient primary endothelial cells showed impaired expression of proinflammatory cytokines and chemokines and adhesion molecules after stimulation with oxLDL. The expression pattern of proinflammatory mediators in the aortas of TRAF6 ECiKO /ApoE Ϫ/Ϫ mice resembles the transcriptional profile previously reported in MyD88 Ϫ/Ϫ /ApoE Ϫ/Ϫ mice, 12 suggesting that endotheliumspecific inhibition of TRAF6-dependent TLR signaling protects mice from the development of atherosclerosis by pre- venting the upregulation of cytokines, chemokines, and adhesion molecules coordinating macrophage influx into the plaque. Consistent with these results, we previously showed that NF-B inhibition specifically in vascular endothelial cells protected ApoE Ϫ/Ϫ mice from atherosclerosis by preventing the expression of proinflammatory factors and the recruitment of monocytes to the developing plaques. 23 Together, these studies suggest that TLRs on the surface of endothelial cells sense modified lipids and activate NF-B signaling in a TRAF6-dependent manner, inducing proinflammatory mediator expression and the recruitment of monocytes into the lesion facilitating plaque growth. Curiously, the atheroprotective effect of endothelial TRAF6 deficiency was observed only in female mice, which are known to develop more severe atherosclerosis than males. Endothelial TRAF6 deficiency reduced atherosclerosis in female mice to levels typically seen in males, suggesting that TRAF6 ablation could prevent plaque growth above a certain threshold that was not reached in male mice, hence the lack of a measurable effect in this group. This is in contrast to the effect of endothelium-specific NF-B inhibition, which very strongly reduced atherosclerosis in both males and females. 23 The stronger effect of NF-B inhibition is not unexpected because TLR signaling is only one of the upstream pathways that can induce NF-B in the endothelium during atherosclerotic plaque development. Monocytes and stromal cells also sense modified lipids and express cytokines that can act on endothelial cells to induce proinflammatory gene expression in a TLR-independent fashion. Therefore, inhibition of TLR signaling is expected to affect only one of the pathways that coordinate proinflammatory gene expression in the vascular endothelium, whereas NF-B inhibition is expected to block nearly every upstream pathway activating the expression of proinflammatory mediators. Thus, TLR-mediated NF-B activation in endothelial cells seems to have an important role in regulating the growth of atherosclerotic plaques, but other TLR-independent pathways acting on the vascular endothelium also contribute to the formation of atherosclerotic lesions.
Although TRAF6 deficiency in endothelial cells protected mice from atherosclerosis, TRAF6 deficiency in macrophages surprisingly exacerbated atherosclerosis in ApoE Ϫ/Ϫ mice. This result was unexpected and provocative, particularly considering the atheroprotective effect observed in mice with complete knockout of MyD88, TLR4, or TLR2, which indicated that TLR signaling plays an overall pathogenic role in atherosclerosis. Our studies suggest that TRAF6 deficiency in macrophages exacerbated atherosclerotic plaque development via different mechanisms. On the one hand, TRAF6-deficient macrophages showed reduced IL-10 expression on stimulation of oxLDL. This is most likely due to inhibition of TRAF6-dependent TLR signaling because MyD88-deficient macrophages also showed impaired IL-10 expression on oxLDL stimulation ( Figure VII in the online-only Data Supplement). Given the antiinflammatory function of IL-10 and the increased atherosclerosis observed in IL-10 -deficient mice, 26 the reduced levels of IL-10 are likely to contribute to the development of more severe atherosclerosis in TRAF6 MYKO / ApoE Ϫ/Ϫ mice. On the other hand, TRAF6 MYKO /ApoE Ϫ/Ϫ mice showed increased necrotic areas in atherosclerotic plaques, suggesting that TRAF6 deficiency sensitized macrophages to cell death. Plaques from TRAF6 MYKO /ApoE Ϫ/Ϫ mice also showed elevated CHOP expression, indicating that increased ER stress might be implicated in sensitizing TRAF6-deficient macrophages to death. Consistent with these in vivo findings, cultured TRAF6-deficient macrophages also showed increased CHOP expression and apoptosis on stimulation with oxLDL. Previous studies showed that LPS prestimulation protects macrophages from ER stress by suppressing the ATF4-CHOP branch of the unfolded protein response in a TRIF-dependent manner. 28 LPS prestimulation failed to suppress CHOP expression in tunicamycin-treated TRAF6-deficient macrophages, demonstrating that TRAF6 is essential for the TLR-mediated protection of macrophages from ER stress. Necrotic death of lipid-laden macrophages within the plaque resulting from increased expression of Chop is considered an important factor contributing to plaque growth. 29 Moreover, ApoE Ϫ/Ϫ mice lacking CHOP developed smaller and less advanced atherosclerotic lesions, 33 further supporting a critical role of the unfolded protein response in atherosclerosis. Thus, increased ER stress and apoptosis of TRAF6-deficient macrophages within the developing plaques are expected to have a proinflammatory effect and to increase the severity of atherosclerosis.
Reduced efferocytosis is considered to be a major contributor to the development to the necrotic core, leading to plaque vulnerability. We found that macrophages lacking TRAF6 showed reduced capacity to scavenge apoptotic debris and expressed reduced levels of IL-10 when exposed to apoptotic cells. Because IL-10 expression is also linked to efferocytosis and the antiinflammatory response of efferocytes within the plaques, impaired IL-10 expression is likely to be at least in part responsible for the reduced clearance of apoptotic macrophages in TRAF6 MYKO /ApoE Ϫ/Ϫ mice. In addition, we showed that TRAF6-deficient macrophages expressed reduced levels of SR-AI/II and CD36, scavenger receptors that have been implicated in the recognition of apoptotic bodies by macrophages and efferocytosis. 30, 31 Thus, impaired scavenger receptor expression, together with reduced IL-10 levels, inhibited the efferocytosis capacity of TRAF6-deficient macrophages, contributing to the formation of a larger necrotic core and more severe atherosclerosis in TRAF6 MYKO / ApoE Ϫ/Ϫ mice.
In contrast to our findings reported here, Stachon and colleagues 34 reported previously that LDL receptor knockout mice reconstituted with TRAF6-deficient fetal liver cells developed levels of atherosclerosis similar to those of mice reconstituted with wild-type fetal liver. This apparent discrepancy is most likely due to the inherent differences in the experimental systems used. Stachon and colleagues showed that Ldlr Ϫ/Ϫ mice reconstituted with TRAF6-deficient fetal liver weighed Ϸ30% less than Ldlr Ϫ/Ϫ mice reconstituted with wild-type fetal liver and showed reduced lipid levels in the blood. We did not observe any effect of myeloid or endothelial TRAF6 deficiency in weight gain or lipid levels, suggesting that the effect observed by Stachon and colleagues is likely caused by the lack of TRAF6 in hematopoietic derived cells other than macrophages. Mice reconstituted with TRAF6-deficient fetal liver were previously shown to develop a progressively lethal inflammatory disease starting as early as 4 weeks after reconstitution. 35, 36 Moreover, mice with T cell-specific TRAF6 deficiency developed a multiorgan inflammatory disease by 10 to 12 weeks after birth resulting from a role of TRAF6 in the maintenance of T-cell homeostasis. 36 It is likely that the reduced weight of TRAF6deficient fetal liver chimeras reported by Stachon and colleagues is also due to the development of a similar multiorgan inflammation, which could affect the development of atherosclerosis and explain their different findings compared with our study.
TRAF6 is a critical adapter molecule not only for TLRs but also for a number of cytokine receptors, including CD40. 19 The role of the CD40/TRAF6 axis in atherosclerosis has previously been studied in mouse models expressing different CD40 mutants that have differential capacity to activate distinct downstream signaling cascades. Lutgens et al 37 reported that ApoE Ϫ/Ϫ mice expressing a CD40 mutant unable to induce TRAF6-mediated signaling were protected from atherosclerosis (Surprisingly, these mice were even more protected than ApoE Ϫ/Ϫ /CD40 Ϫ/Ϫ mice), suggesting that CD40-TRAF6 signaling is an important pathogenic factor in atherosclerosis. These authors suggested that inhibition of the CD40-TRAF6 axis in MHC ϩ myeloid cells is responsible for the observed protective effect in their mice. Our findings that mice with myeloid-specific knockout of TRAF6 develop more severe atherosclerosis demonstrate that other upstream receptors, most likely TLRs, play a prominent role in inducing TRAF6-dependent signals that overshadow the potential role of the CD40-TRAF6 axis in regulating myeloid cell responses in atherosclerosis.
Taken together, our results unravel a previously unanticipated complexity in the role of TRAF6 as a downstream mediator of TLR signaling pathways in the development of atherosclerosis. The TLR/TRAF6/IB kinase/NF-B pathway plays a predominantly pathogenic role in the development of atherosclerosis in female mice by acting in endothelial cells, where it senses modified lipids and induces the expression of proinflammatory mediators that sustain the constant adhesion and recruitment of macrophages, promoting plaque growth. On the other hand, TRAF6 deficiency in myeloid cells exacerbates the development of atherosclerosis in both males and females by inhibiting the expression of IL-10, sensitizing macrophages to ER stress-induced death, and reducing their efferocytosis capacity. Thus, TLR-induced signals converge on TRAF6 to regulate the pathogenesis of atherosclerosis by controlling cell-specific cellular responses that exert diverse and opposing effects in plaque development.
